Multiple drug targets for the treatment of influenza identified using AI program

FHS
July 1, 2023
3:46 pm

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’) Programme with CytoReason.

SPY Stock analysis and why SPY stock may start selling soon

September 9, 2023

J&J’s Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with high-risk smoldering multiple myeloma, a precursor to

November 6, 2024

Novel Drug-Device Shows Efficacy for High-Grade Cervical Lesions

SAN DIEGO — A novel, noninvasive, photodynamic drug-device combination was efficacious and safe for patients with cervical histologic high-grade squamous intraepithelial lesions (HSIL), a randomized

March 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.